Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas

Contributed by: Business Wire

Tags

Science
Other Science
Biotechnology
Research
Pharmaceutical
Oncology
Health
FDA
IKS03